{
    "clinical_study": {
        "@rank": "97368", 
        "arm_group": [
            {
                "arm_group_label": "mildronate", 
                "arm_group_type": "Experimental", 
                "description": "infusion of mildronate"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "infusion of placebo mildronate"
            }
        ], 
        "brief_summary": {
            "textblock": "This study seeks to evaluate the efficacy and safety of mildronate injection in treating\n      acute ischemic stroke"
        }, 
        "brief_title": "Efficacy and Safety of Mildronate for Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "a randomized, double-blind, placebo-controlled phase II multicenter trial is conducted to\n      evaluate the efficacy and safety of mildronate injection in patients with acute ischemic\n      stroke. patients will be randomized  to receive a 14-day treatment of placebo or mildronate\n      (500mg/5ml/each).Primary end-point is the modified Rankin scale at 3 monthes. Secondary\n      end-point is the NIHSS scores and the Barthel index at 8 days and 15days. The safety\n      end-point  is defined as the incidence of adverse events, the change of Samples for routine\n      laboratory tests and vital signs. Analysis is by intention to treat."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - have a clinical diagnosis of acute ischemic stroke have CT or MRI brain imaging NIHSS\n        scores:5~22 on the first stage\n\n        Exclusion Criteria:\n\n        - have other intracranial pathologies are pregnant or nursing have significant drug or\n        alcohol misuse have been in a clinical trial in the past 3 months are unlikely to be\n        available for follow-up have been given thrombolytic therapy or medication forbidden by\n        study protocol have a neurological or psychiatric disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800357", 
            "org_study_id": "xijing-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "mildronate", 
                "description": "infusion of mildronate(500mg) once a day and for 14 days", 
                "intervention_name": "infusion of mildronate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "infusion of plabcebo once a day and for 14 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "mildronate", 
                    "placebo"
                ], 
                "description": "infusion of aspirin (100mg) once a day for days", 
                "intervention_name": "aspirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "3-(2,2,2-trimethylhydrazine)propionate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "randomized trial", 
            "acute ischemic stroke", 
            "mildronate"
        ], 
        "lastchanged_date": "February 25, 2013", 
        "location": {
            "contact": {
                "email": "zhaogang@fmmu.edu.cn", 
                "last_name": "Gang Zhao, MD", 
                "phone": "02984775361"
            }, 
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shaanxi", 
                    "zip": "710032"
                }, 
                "name": "the Department of Neurology , Xijing Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Yi Zhu, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Guang Yun Zhang, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial", 
        "overall_contact": {
            "email": "zhaogang@fmmu.edu.cn", 
            "last_name": "Gang Zhao, MD", 
            "phone": "02984775361"
        }, 
        "overall_official": [
            {
                "affiliation": "the Department of Neurology , Xijing Hospital", 
                "last_name": "Gang Zhao, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "the Department of Neurology , Xijing Hospital", 
                "last_name": "Yi Zhu, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the modified Rankin scale", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "NIHSS scores", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "NIHSS scores", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "the Barthel index", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "the Barthel index", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }
        ], 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}